This post was originally published on this site Selinexor in combination with dexamethasone and Pomalyst (pomalidomide) leads to strong and durable anti-cancer responses, without significant side effects, in patients with relapsed or refractory multiple myeloma who received at least two prior therapies, data from a Phase 1/2b trial show. The findings were presented in a poster…
This post was originally published on this site A violinist with vasculitis, two Texas politicians and a pharmaceutical company whose marijuana-derived therapy helps kids with Dravet syndrome were among winners of the 2019 Rare Impact Awards. Officials of the National Organization for Rare Disorders (NORD) presented the awards during a June 22 dinner attended by…
This post was originally published on this site BeiGene’s investigational anti-PD-1 inhibitor tislelizumab is well-tolerated and showed early signs of efficacy in patients with advanced nasopharyngeal cancer, with more than 40% of patients achieving a response to treatment, preliminary Phase 2 results show. The findings were presented at the 2019 American Society of Clinical Oncology…
This post was originally published on this site The European Commission (EC) has approved Pfizer‘s Talzenna (talazoparib) for the treatment of patients with advanced forms of HER2-negative breast cancer with BRCA mutations who have been treated with chemotherapy — before or after surgery, with an anthracycline and/or a taxane — or were not eligible to…
This post was originally published on this site Long-term antibiotic treatment, aimed at altering the bacterial population in the gut, was found to reduce the inflammation and amyloid plaque formation that is a hallmark of Alzheimer’s disease — but only in male mice. The same treatment had no effect on female mice, a study found.…
This post was originally published on this site Researchers from Clemson University and doctors from South Carolina’s Prisma Health-Upstate are collaborating to develop a screening tool that can identify ovarian cancer in its earlier stages, or even before it arises. Ovarian cancer is one of the deadliest for women. The best way to increase survival…
This post was originally published on this site Zanubrutinib in combination with Gazyva (obinutuzumab) leads to clinically meaningful responses and is well-tolerated by patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma, a Phase 1b trial shows. The findings were announced at an oral presentation titled, “Zanubrutinib Plus Obinutuzumab in Patients with Chronic…
This post was originally published on this site The immune checkpoint inhibitor Keytruda (pembrolizumab) was found to be a safe treatment for different cancer types among people living with HIV, data from a Phase 1 trial show. The results are likely applicable to other immune checkpoint inhibitors targeting the same pathway as Keytruda, the investigators said. The…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has authorized the initiation of a Phase 2 clinical trial testing Hemispherx Biopharma‘s Ampligen (rintatolimod), in combination with aspirin or aspirin plus Intron A (interferon-alpha 2b), as a treatment for prostate cancer patients before surgery. The randomized clinical trial (NCT03899987)…
This post was originally published on this site Addressing the need for shared, comprehensive data to identify targets and provide personalized treatment road maps, the Multiple Myeloma Research Foundation (MMRF) is launching a centralized data hub called MMRF CureCloud. Designed to ultimately speed delivery of precision medicine to people with multiple myeloma, CureCloud is a…
